Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker NXTC
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Nov 13, 2026 | SCHEDULE 13G/A (amended) | NXTC NextCure, Inc. | Michael Cho | 475,626 | 10.0% | SCHEDULE 13G/A ↗ |
| Nov 13, 2026 | SCHEDULE 13G/A (amended) | NXTC NextCure, Inc. | Affinity Asset Advisors, LLC | 475,626 | 10.0% | SCHEDULE 13G/A ↗ |
| Oct 20, 2026 | SCHEDULE 13G | NXTC NextCure, Inc. | Jianping Huang | 455,001 | 9.9% | SCHEDULE 13G ↗ |
| Oct 20, 2026 | SCHEDULE 13G | NXTC NextCure, Inc. | JP Sailing Capital Ltd | 455,001 | 9.9% | SCHEDULE 13G ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | NXTC NextCure, Inc. | William Blank | 64,464 | 1.6% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | NXTC NextCure, Inc. | Matthew Sesterhenn | 64,464 | 1.6% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | NXTC NextCure, Inc. | Squadron Capital Management LLC | 64,464 | 1.6% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | NXTC NextCure, Inc. | Squadron Master Fund LP | 64,464 | 1.6% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | NXTC NextCure, Inc. | Neil Shahrestani | 502,672 | 10.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | NXTC NextCure, Inc. | Ikarian Capital, LLC | 502,672 | 10.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G | NXTC NextCure, Inc. | Daniel Schneeberger | 722,419 | 15.8% | SCHEDULE 13G ↗ |
| Aug 14, 2026 | SCHEDULE 13G | NXTC NextCure, Inc. | ADAR1 Capital Management, LLC | 722,419 | 15.8% | SCHEDULE 13G ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | NXTC NextCure, Inc. | Michael Cho | 274,073 | 6.4% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | NXTC NextCure, Inc. | Affinity Asset Advisors, LLC | 274,073 | 6.4% | SCHEDULE 13G/A ↗ |
| Aug 12, 2026 | SCHEDULE 13G | NXTC NextCure, Inc. | Phillip Gross | 277,202 | 7.7% | SCHEDULE 13G ↗ |
| Aug 12, 2026 | SCHEDULE 13G | NXTC NextCure, Inc. | Robert Atchinson | 277,202 | 7.7% | SCHEDULE 13G ↗ |
| Aug 12, 2026 | SCHEDULE 13G | NXTC NextCure, Inc. | Adage Capital Management, L.P. | 277,202 | 7.7% | SCHEDULE 13G ↗ |
| May 13, 2026 | SCHEDULE 13G/A (amended) | NXTC NextCure, Inc. | Devesh Gandhi | 176,057 | 4.9% | SCHEDULE 13G/A ↗ |
| May 13, 2026 | SCHEDULE 13G/A (amended) | NXTC NextCure, Inc. | SilverArc Capital Management, LLC | 176,057 | 4.9% | SCHEDULE 13G/A ↗ |
| May 6, 2026 | SCHEDULE 13G/A (amended) | NXTC NextCure, Inc. | Tang Renhong | 338,636 | 9.4% | SCHEDULE 13G/A ↗ |
| May 6, 2026 | SCHEDULE 13G/A (amended) | NXTC NextCure, Inc. | Ren Jinsheng | 338,636 | 9.4% | SCHEDULE 13G/A ↗ |
| May 6, 2026 | SCHEDULE 13G/A (amended) | NXTC NextCure, Inc. | Simcere Pharmaceutical Group Limited | 338,636 | 9.4% | SCHEDULE 13G/A ↗ |
| May 6, 2026 | SCHEDULE 13G/A (amended) | NXTC NextCure, Inc. | Simcere Zaiming Pharmaceutical Co., Ltd. | 338,636 | 9.4% | SCHEDULE 13G/A ↗ |
| May 6, 2026 | SCHEDULE 13G/A (amended) | NXTC NextCure, Inc. | Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. | 338,636 | 9.4% | SCHEDULE 13G/A ↗ |
| May 6, 2026 | SCHEDULE 13G/A (amended) | NXTC NextCure, Inc. | Simcere Zaiming, Inc. | 338,636 | 9.4% | SCHEDULE 13G/A ↗ |
| Mar 5, 2026 | SCHEDULE 13D/A (amended) | NXTC NextCure, Inc. | Dr. James I. Healy ("Healy") | 222,654 | 7.1% | SCHEDULE 13D/A ↗ |
| Mar 5, 2026 | SCHEDULE 13D/A (amended) | NXTC NextCure, Inc. | Sofinnova Management IX, L.L.C. ("SM IX") | 222,654 | 7.1% | SCHEDULE 13D/A ↗ |
| Mar 5, 2026 | SCHEDULE 13D/A (amended) | NXTC NextCure, Inc. | Sofinnova Venture Partners IX, L.P. ("SVP IX") | 222,654 | 7.1% | SCHEDULE 13D/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | NXTC NextCure, Inc. | William Blank | 271,127 | 9.9% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | NXTC NextCure, Inc. | Matthew Sesterhenn | 271,127 | 9.9% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | NXTC NextCure, Inc. | Squadron Capital Management LLC | 271,127 | 9.9% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | NXTC NextCure, Inc. | Squadron Master Fund LP | 271,127 | 9.9% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G | NXTC NextCure, Inc. | Neil Shahrestani | 363,035 | 10.0% | SCHEDULE 13G ↗ |
| Feb 17, 2026 | SCHEDULE 13G | NXTC NextCure, Inc. | Ikarian Capital, LLC | 363,035 | 10.0% | SCHEDULE 13G ↗ |
| Feb 13, 2026 | SCHEDULE 13G/A (amended) | NXTC NextCure, Inc. | Pfizer Ventures (US) LLC (IRS Indentification No. 82-5524518 ) | 131,109 | 2.5% | SCHEDULE 13G/A ↗ |
| Feb 13, 2026 | SCHEDULE 13G/A (amended) | NXTC NextCure, Inc. | Pfizer Inc. (IRS Identification No.: 13-5315170) | 157,646 | 3.0% | SCHEDULE 13G/A ↗ |
| Feb 12, 2026 | SCHEDULE 13G | NXTC NextCure, Inc. | Devesh Gandhi | 176,057 | 5.0% | SCHEDULE 13G ↗ |
| Feb 12, 2026 | SCHEDULE 13G | NXTC NextCure, Inc. | SilverArc Capital Management, LLC | 176,057 | 5.0% | SCHEDULE 13G ↗ |
| Jan 29, 2026 | SCHEDULE 13G/A (amended) | NXTC NextCure, Inc. | Michael Cho | 348,607 | 10.0% | SCHEDULE 13G/A ↗ |
| Jan 29, 2026 | SCHEDULE 13G/A (amended) | NXTC NextCure, Inc. | Affinity Asset Advisors, LLC | 348,607 | 10.0% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | NXTC NextCure, Inc. | Affinity Asset Advisors, LLC | 191,882 | 7.2% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | NXTC NextCure, Inc. | Affinity Healthcare Fund, LP | 191,882 | 7.2% | SCHEDULE 13G/A ↗ |
| Oct 24, 2025 | SCHEDULE 13G | NXTC NextCure, Inc. | William Blank | 173,861 | 6.5% | SCHEDULE 13G ↗ |
| Oct 24, 2025 | SCHEDULE 13G | NXTC NextCure, Inc. | Matthew Sesterhenn | 173,861 | 6.5% | SCHEDULE 13G ↗ |
| Oct 24, 2025 | SCHEDULE 13G | NXTC NextCure, Inc. | Squadron Capital Management LLC | 173,861 | 6.5% | SCHEDULE 13G ↗ |
| Oct 24, 2025 | SCHEDULE 13G | NXTC NextCure, Inc. | Squadron Master Fund LP | 154,021 | 5.8% | SCHEDULE 13G ↗ |
| Aug 19, 2025 | SCHEDULE 13G | NXTC NextCure, Inc. | Tang Renhong | 338,636 | 12.7% | SCHEDULE 13G ↗ |
| Aug 19, 2025 | SCHEDULE 13G | NXTC NextCure, Inc. | Ren Jinsheng | 338,636 | 12.7% | SCHEDULE 13G ↗ |
| Aug 19, 2025 | SCHEDULE 13G | NXTC NextCure, Inc. | Simcere Pharmaceutical Group Limited | 338,636 | 12.7% | SCHEDULE 13G ↗ |
| Aug 19, 2025 | SCHEDULE 13G | NXTC NextCure, Inc. | Hainan Simcere Zaiming Pharmaceutical Co., Ltd. | 338,636 | 12.7% | SCHEDULE 13G ↗ |
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 7:14 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances